Psychomotor changes in major depressive disorder during sertraline treatment

Neuropsychobiology

Volumn 59, Issue 1, 2009, Pages 34-42

  Schrijvers, D ^a   Maas, Y J ^a   Pier, M P B I ^c   Madani, Y ^b   Hulstijn, W ^a,d   Sabbe, B G C ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Psychiatric Hospital Sint Norbertus   (Belgium)

^c Prins Claus Centre   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Dopamine; Major depression; Psychomotor retardation; Selective serotonin reuptake inhibitor; Serotonin; Sertraline

Indexed keywords

CITALOPRAM; FLUPENTIXOL; MELITRACEN; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 61449209923     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205516     Document Type: Article

References (42)

1. Sobin C, Sackeim HA: Psychomotor symptoms of depression. Am J Psychiatry 1997;154:4-17.
2. Schrijvers D, Hulstijn W, Sabbe BGC: Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord 2008;109:1-20.
3. Parker G: Classifying depression: should paradigms lost be regained? Am J Psychiatry 2000;157:1195-1203.
4. Malhi GS, Parker GB, Greenwood J: Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand 2005;111:94-105.
5. Hamilton MA: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
6. Widlöcher D: Retardation: A basic emotional response? in Davis JH, Maas JW (eds): The Affective Disorders. Washington, American Psychiatric Press, 1983.
7. Hegerl U, Mergl R, Henkel V, Pogarell O, Muller-Siecheneder F, Frodl T, Juckel G: Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression. Psychopharmacology (Berl) 2005;178:58-66.
8. Mergl R, Pogarell O, Juckel G, Rihl J, Henkel V, Frodl T, Müller-Siecheneder F, Karner M, Tigges P, Schröter A, Hegerl U: Hand-motor dysfunction in depression: characteristics and pharmacological effects. Clin EEG Neurosci 2007;38:82-88.
9. Sabbe B, van Hoof J, Hulstijn W, Zitman F: Changes in fine motor retardation in depressed patients treated with fluoxetine. J Affect Disord 1996;40:149-157.
10. Mann JJ, Kapur SA: A dopaminergic hypothesis of major depression. Symposium dopamine receptor subtypes in neurological and psychiatric diseases. Clin Neuropharmacol 1995;18(suppl 1):S57-S65.
11. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP: Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997;27:1247-1256.
12. Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot J: Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001;158:314-316.
13. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NP, Wilson AA, Houle S: Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 2006;163:1594-1602.
14. Bolden-Watson C, Richelson E: Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029.
15. Richelson E: Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 2003;64(suppl 13):S5-S12.
16. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-258.
17. Alpert M, Pouget ER, Silva RR: Reflections of depression in acoustic measures of the patient's speech. J Affect Disord 2001;66:59-69.
18. Ravindran AV, Teehan MD, Bakish D, Yatham L, Oreilly R, Fernando ML, Manchanda R, Charbonneau Y, Buttars J: The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol 1995;10:273-281.
19. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, version 2.0, Dutch translation, van Groenestijn MAC, Akkerhuis GW, Kupka RW, Schneider N, Nolen WA (eds). Lisse, Swets and Zeitlinger BV, 1999.
20. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
21. Pier MP, Hulstijn W, Sabbe BG: Differential patterns of psychomotor functioning in unmedicated melancholic and nonmelancholic depressed patients. J Psychiatr Res 2004;38:425-435.
22. Sabbe B, Hulstijn W, Van Hoof J, Zitman F: Fine motor retardation and depression. J Psychiatr Res 1996;30:295-306.
23. Sabbe B, Hulstijn W, van Hoof J, Tuynman-Qua HG, Zitman F: Retardation in depression: assessment by means of simple motor tasks. J Affect Disord 1999;55:39-44.
24. Morrens M, Hulstijn W, Sabbe B: Psychomotor slowing in schizophrenia. Schizophr Bull 2007;33:1038-1053.
25. Sabbe B, van Hoof J, Hulstijn W, Zitman F: Depressive retardation and treatment with fluoxetine: assessment of the motor component. J Affect Disord 1997;43:53-61.
26. Newhouse PA, Krishnan KRR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM: A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000;61:559-568.
27. McEntee W, Ko G, Richter E: Sertraline and nortriptyline: heart rate, cognitive improvement and quality of life in the depressed elderly. Eur Neuropsychopharmacol 1996;6(suppl 3):36.
28. Sechter D, Troy S, Paternetti S, Boyer P: A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999;17:1-8.
29. Sherwood N: Comparative behavioural toxicity of the selective serotonin reuptake inhibitors. Hum Psychopharmacol 1995;10:S159-S162.
30. Lane RM, O'Hanlon JF: Cognitive and psychomotor effects of antidepressants with emphasis on selective serotonin reuptake inhibitors and the depressed elderly patient. Ger J Psychiatry 1999;2:1-42.
31. Schmitt JAJ, Ramaekers JG, Kruizinga MJ, van Boxtel MPJ, Vuurman EFPM, Riedel WJ: Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002;16:207-214.
32. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE: Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-312.
33. Furlan PM, Kallan MJ, Ten Have T, Pollock BG, Katz I, Lucki I: Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Am J Geriatr Psychiatry 2001;9:429-438.
34. Allain H, Lieury A, Brunet-Bourgin F, Mirabaud C, Trebon P, Le Coz F, Gandon JM: Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology (Berl) 1993;106(suppl):56-61.
35. Fairweather DB, Kerr JS, Hindmarch I: The effects of moclobemide on psychomotor performance and cognitive function. Int Clin Psychopharmacol 1993;8:43-47.
36. Gattaz WF, Vogel P, Kick H, Kohnen R: Moclobemide versus fluoxetine in the treatment of inpatients with major depression. J Clin Psychopharmacol 1995;15(suppl 2):35S-40S.
37. McClure SM, Berns G, Montague PR: Temporal prediction errors in a passive learning task activate human striatum. Neuron 2003;38:339-346.
38. Dunlop BW, Nemeroff CB: The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-337.
39. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, DubéS, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602.
40. Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M: Which depressions respond to placebo? Psychiatry Res 1986;18:217-226.
41. Peselow ED, Sanfilipo MP, Difiglia C, Fieve RR: Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 1992;49:1324-1334.
42. Parker G, Manicavasagar V: Modelling and Managing the Depressive Disorders: A Clinical Guide. Cambridge, Cambridge University Press, 2005.